Agreement with Noahnix, a Specialist in Biomaterial Coatings
[Asia Economy Honam Reporting Headquarters Reporter Yoon Jamin] Jeonnam National University Hospital (Director Ahn Young-geun) has signed a technology transfer agreement with Noahnix Co., Ltd. (CEO Choi Hyung-jun), a company specializing in biomaterial coating, for the technology of 'Medical Stents and Their Surface Treatment Methods.'
Jeonnam National University Hospital announced on the 17th that the agreement was signed on the 15th with hospital officials including Director Ahn Young-geun, Director Kim Jae-min of the Biomedical Research Institute, Professor Jung Myung-ho of the Department of Cardiology, and Noahnix CEO Choi Hyung-jun.
The transferred technology, 'Medical Stents and Their Surface Treatment Methods,' was jointly researched and developed by Professor Jung Myung-ho's cardiology research team and the Korea Cardiovascular Stent Research Institute through support from the Ministry of Health and Welfare's Cardiovascular Convergence Research Center project. It was filed and registered with the support of Jeonnam National University Hospital's Biomedical Research Institute.
This technology is a surface treatment method that uses atmospheric pressure plasma to impart a very high level of hydrophilicity (property of affinity to water) to stents used to expand blood vessels narrowed by various diseases in a short time, reducing problems such as thrombosis during surgery.
Additionally, it has excellent biocompatibility, preventing secondary contamination such as inflammation when coating drugs on the stent, and enables the rapid removal of organic substances that may remain on the surface.
Professor Jung's team has been conducting research from November 2013 to October 2019 under the Ministry of Health and Welfare's Cardiovascular Convergence Research Center project, collaborating with experts from industry, academia, research institutes, and hospitals to address cardiovascular diseases and unmet medical needs in the aging era.
Furthermore, Professor Jung is conducting investigator-initiated exploratory clinical research using the TIGERevolutioN, a biopolymer-free drug-eluting stent jointly developed with the stent specialist company CGBio Co., Ltd.
He is also participating in a government-wide full-cycle medical device R&D project titled 'Development of a Cardiovascular Multifunctional Bioabsorbable Polymer Stent System,' preparing to develop differentiated domestic stents for the coronary artery stent market, which currently depends on imported products.
Professor Jung said, "This technology transfer is an achievement of developing core technologies needed in the industry based on Jeonnam National University Hospital's excellent cardiovascular medical technology. I believe it will greatly help establish the National Cardiovascular Center and strengthen the position of research-oriented hospitals in the future."
Meanwhile, Professor Jung has authored a total of 1,836 papers and has been the top publisher in the Korean Society of Cardiology for 19 consecutive years.
He has trained 22 medical doctors through experiments on 3,578 pig hearts and is nicknamed "Pig Father." Since 2005, he has registered 80,803 patients in the Korean Acute Myocardial Infarction Registry, conducting a world-class registry study.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
